How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers

Discussion
1

This survey of HBCs shows limited implementation of LTBI guidelines, and provides some insight into barriers to implementation, including shortage of products (eg, PPD), high costs (eg, IGRAs), and lack of regulatory approval of newer treatments (eg, rifapentine).

URL: https://onlinelibrary.wiley.com/doi/epdf/10.1002/hsr2.158

Faust Health Sc Rep 2020.pdf (1.3 MB)